Barclays raised the firm’s price target on Pfizer to $32 from $30 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says there is still more room to upside for 2024 numbers as it looks for a clearer set sustainable portfolio drivers and clarity on Pfizer’s 2025 dynamics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- PFE Earnings: Pfizer Blows Past Estimates in Q2
- Options Volatility and Implied Earnings Moves Today, July 30, 2024
- Notable companies reporting before tomorrow’s open
- Pfizer (NYSE:PFE) Q2 Earnings Preview: Here’s What to Expect
- Options Volatility and Implied Earnings Moves This Week, July 29 – August 02, 2024